RecallRadar

FDA Drug recall D-0658-2020

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (ND…

On 2020-01-22 the FDA classified a Class II recall of Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (ND… by Hikma Pharmaceuticals Usa, citing presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS).

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0658-2020
ClassificationClass II
Statusterminated
Initiated2019-12-17
Published2020-01-22
Last updated2026-09-13 11:52 UTC
CompanyHikma Pharmaceuticals Usa
DistributionUS

Product

Ketorolac Tromethamine Injection, USP 60 mg/2 mL (30 mg/mL), packaged in 2 mL Single Dose Vials (NDC 0641-6043-01), 25 vials/shelf-pack (NDC 0641-6043-25), For IM Use Only, Rx only, Manufactured by: WEST-WARD Eatontown, NJ 07724 USA.

Reason

Presence of Particulate Matter: particles identified as polydimethylsiloxane (PDMS)

Identifiers

ndc0641-6043-01
ndc0641-6043-25
ndc0641-6042-01
ndc0641-6042-25
ndc0641-6041-01
ndc0641-6041-25
code_info038368, Exp. Mar 2020; 058314, Exp. May 2020; 078305, 078307, Exp. July 2020; 118362 Exp. Nov 2020

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0658-2020%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.